• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

The effect of chronic exposure to metformin in a new type-2 diabetic NONcNZO10/LtJ mouse model of stroke
CONCLUSION: The study suggests that the prolonged effect of metformin-induced euglycemia promoted the microglial activation, reduced neuronal cell death, and improved the overall survival following stroke, without any change in infarct size.PMID:35792967 | DOI:10.1007/s43440-022-00382-z
Source: Pharmacological Reports - July 6, 2022 Category: Drugs & Pharmacology Authors: Rashmi Kumari Lisa Willing Scot R Kimball Ian A Simpson Source Type: research

Identification and Validation of Major Cardiovascular Events in the United Kingdom Data Sources Included in a Multi-database Post-authorization Safety Study of Prucalopride
ConclusionsGiven the limitations of relying solely on computer algorithms to identify cardiovascular outcomes, validation with clinical review is essential to guide interpretation.
Source: Drug Safety - February 19, 2021 Category: Drugs & Pharmacology Source Type: research

Comparative safety and effectiveness of direct oral anticoagulants in patients with atrial fibrillation in clinical practice in Scotland
ConclusionsAll DOACs were similarly effective in preventing strokes and systemic embolisms, while patients being treated with rivaroxaban exhibited the highest bleeding risks. Observed differences in the risks of all ‐cause mortality, myocardial infarction, and pulmonary embolism warrant further research.
Source: British Journal of Clinical Pharmacology - November 13, 2018 Category: Drugs & Pharmacology Authors: Tanja Mueller, Samantha Alvarez ‐Madrazo, Chris Robertson, Olivia Wu, Marion Bennie Tags: ORIGINAL ARTICLE Source Type: research

Use of direct oral anticoagulants in patients with atrial fibrillation in Scotland: Applying a coherent framework to drug utilisation studies
ConclusionsIn Scotland, adherence to DOAC treatment was good, and switching from DOAC to warfarin was low. However, discontinuation and persistence rates were variable—although treatment interruptions were often temporary.To decrease the inconsistencies in drug utilisation methods and facilitate meaningful study comparison, the use of a coherent framework—using a combination of discontinuation, persistence, and adherence—and the standardisation of measurements is advocated.
Source: Pharmacoepidemiology and Drug Safety - July 28, 2017 Category: Drugs & Pharmacology Authors: Tanja Mueller, Samantha Alvarez ‐Madrazo, Chris Robertson, Marion Bennie Tags: ORIGINAL REPORT Source Type: research

Eliquis use within NHS Scotland for the prevention of stroke and systemic embolism
Bristol-Myers Squibb and Pfizer Ltd. has announced that the Scottish Medicines Consortium (SMC) accepted the novel oral anticoagulant (NOAC) Eliquis (apixaban) for use within NHS Scotland for the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (AF) with one or more risk factors.
Source: Pharmacy Europe - February 13, 2013 Category: Drugs & Pharmacology Source Type: news